Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Neurology
Biotech
Lilly saves gene therapy biotech with $18M upfront deal
Sangamo can earn up to $1.4 billion in fees and milestones, as well as tiered royalties, if Lilly opts to pursue all five possible targets.
Darren Incorvaia
Apr 3, 2025 6:00pm
Clario acquires WCG's neuro-focused eCOA business
Mar 12, 2025 3:40pm
Takeda fronts $46M for 2nd small molecule collab with BridGene
Feb 25, 2025 8:00am
Lilly's next focus: Testing incretins in neuro, immunology fields
Feb 6, 2025 2:35pm
Biogen shrinks research team, prioritizes external innovation
Jan 22, 2025 4:10pm
Trace uses $101M series A to go after same ALS target as Lilly
Nov 12, 2024 7:00am
